Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 19;9(2):e024561.
doi: 10.1136/bmjopen-2018-024561.

Multicentre randomised controlled trial to investigate usefulness of the rapid diagnostic βLACTA test performed directly on bacterial cell pellets from respiratory, urinary or blood samples for the early de-escalation of carbapenems in septic intensive care unit patients: the BLUE-CarbA protocol

Marc Garnier  1   2   3 , Salah Gallah  4 , Sophie Vimont  3   4 , Yahia Benzerara  4 , Vincent Labbe  2 , Anne-Laure Constant  5 , Shidasp Siami  6 , Emmanuel Guerot  7 , Fabrice Compain  8 , Jean-Luc Mainardi  8 , Mélissa Montil  9 , Christophe Quesnel  1   3 ; BLUE-CarbA study group.
Collaborators, Affiliations

Multicentre randomised controlled trial to investigate usefulness of the rapid diagnostic βLACTA test performed directly on bacterial cell pellets from respiratory, urinary or blood samples for the early de-escalation of carbapenems in septic intensive care unit patients: the BLUE-CarbA protocol

Marc Garnier et al. BMJ Open. .

Abstract

Introduction: The dramatic increase of the incidence of infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) has led to an increase of 50% of carbapenem consumption all around Europe in only 5 years. This favours the spread of carbapenem-resistant Gram-negative bacilli (GNB), causing life-threatening infections. In order to limit use of carbapenems for infections actually due to ESBL-PE, health authorities promote the use of rapid diagnostic tests of bacterial resistance. The objective of this work conducted in the intensive care unit (ICU) is to determine whether an early de-escalation of empirical carbapenems guided by the result of the βLACTA test is not inferior to the reference strategy of de-escalating carbapenems after the antibiogram result has been rendered.

Methods and analysis: This multicentre randomised controlled open-label non-inferiority clinical trial will include patients suffering from respiratory and/or urinary and/or bloodstream infections documented with GNB on direct examination and empirically treated with carbapenems. Empirical carbapenems will be adapted before the second dose depending on the results of the βLACTA test performed directly on the microbiological sample (intervention group) or after 48-72 hours depending on the definite antibiogram (control group). The primary outcome will combine 90-day mortality and percentage of infection recurrence during the ICU stay. The secondary outcomes will include the number of carbapenems defined daily doses and carbapenem-free days after inclusion, the proportion of new infections during ICU stay, new colonisation of patients' digestive tractus with multidrug-resistant GNB, ICU and hospital length of stay and cost-effectiveness ratio.

Ethics and dissemination: This protocol has been approved by the ethics committee of Paris-Ile-de-France IV, and will be carried out according to the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines. The results of this study will be disseminated through presentation at scientific conferences and publication in peer-reviewed journals.

Trial registration number: NCT03147807.

Keywords: antibiotic de-escalation; antibiotic resistance; carbapenem; intensive care unit; rapid diagnostic test; respiratory infection.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Study design. AST, antimicrobial susceptibility test; BLT, βLACTA test; GNB, Gram-negative bacilli.
Figure 2
Figure 2
BLUE-CarbA schedule of forms and procedures. CRT, clinical research technician; PI, principal investigator.
See this image and copyright information in PMC

References

    1. Holmes AH, Moore LS, Sundsfjord A, et al. . Understanding the mechanisms and drivers of antimicrobial resistance. Lancet 2016;387:176–87. 10.1016/S0140-6736(15)00473-0 - DOI - PubMed
    1. European Center for Disease Control. European Country Overview of Antimicrobial Consumption. 2018. https://www.ecdc.europa.eu/en/antimicrobial-consumption/database/country... (Accessed 9 May 2018).
    1. Knothe H, Shah P, Krcmery V, et al. . Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983;11:315–7. 10.1007/BF01641355 - DOI - PubMed
    1. Kliebe C, Nies BA, Meyer JF, et al. . Evolution of plasmid-coded resistance to broad-spectrum cephalosporins. Antimicrob Agents Chemother 1985;28:302–7. 10.1128/AAC.28.2.302 - DOI - PMC - PubMed
    1. Sirot D, Sirot J, Labia R, et al. . Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel beta-lactamase. J Antimicrob Chemother 1987;20:323–34. 10.1093/jac/20.3.323 - DOI - PubMed

Publication types

MeSH terms

Associated data